3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Renal Cell
5
Colorectal Neoplasms
4
Gastrointestinal Neoplasms
2
Solid Tumors
1
Sarcoma
1
Recurrence
1
Neoplasms
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Disease Progression
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Tumors
1
Advanced Adult Hepatocellular Carcinoma
1
Interventions
Carboplatin
69
Paclitaxel
63
Cisplatin
32
Topotecan
29
Gemcitabine
21
Docetaxel
20
Cyclophosphamide
18
Filgrastim
17
liposomal doxorubicin
15
Peripheral Blood Stem Cell Transplantation
15
Bevacizumab
14
sargramostim
11
Taxes
10
Drug Therapy
10
Therapeutics
7
Psychiatric Rehabilitation
7
Immunohistochemistry
7
Erlotinib Hydrochloride
7
Amifostine
7
Melphalan
6
Chemotherapy, Adjuvant
6
rucaparib
5
pembrolizumab
5
mirvetuximab soravtansine
5
ixabepilone
5
Surgical Procedures, Operative
5
Mass Spectrometry
5
Interleukin-12 Subunit p35
5
Flow Cytometry
5
Etoposide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Ovarian Epithelial
×
tivozanib
×
Clear all
NCT01853644
2021-10-12
TIVO
Northwestern University
Phase 2
Completed
31 enrolled
12 charts